Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome

Mostrar todas las versiones(2)

Introduction: COVID-19 morbimortality is mainly associated with development of severe acute respiratory syndrome (SARS), which has been related to an augmented immune response of the host with elevated circulating cytokines. Methods: In this is a prospective, multicenter, single arm (compared with a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Iastrebner, Marcelo, Castro, Joaquín, García Espina, Edgardo, Lettieri, Carolina, Payaslian, Silvio, Cuesta, María Celia, Gutiérrez Fernández, Pablo, Mandrile, Araceli, Contreras, Angela Paola, Gervasoni, Sebastián, Verde, Gabriel, Galetti, Cayetano, Minoldo, Estefanía, Caruso, Vanesa
Formato: Artículo revista
Lenguaje:Inglés
Publicado: Universidad Nacional Cba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021
Materias:
coronavirus infections
Janus kinase inhibitors
respiratory distress syndrome, adult
infecciones por coronavirus
inhibidores de las cinasas Janus
síndrome de dificultad respiratoria del adulto
infecções por coronavirus
inibidores de janus quinases
síndrome do desconforto respiratório do adulto
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/32800
Aporte de:
Revistas de la UNC de Universidad Nacional de Córdoba
id I10-R10article-32800
record_format ojs
institution Universidad Nacional de Córdoba
institution_str I-10
repository_str R-10
container_title_str Revistas de la UNC
language Inglés
format Artículo revista
topic coronavirus infections
Janus kinase inhibitors
respiratory distress syndrome, adult
infecciones por coronavirus
inhibidores de las cinasas Janus
síndrome de dificultad respiratoria del adulto
infecções por coronavirus
inibidores de janus quinases
síndrome do desconforto respiratório do adulto
spellingShingle coronavirus infections
Janus kinase inhibitors
respiratory distress syndrome, adult
infecciones por coronavirus
inhibidores de las cinasas Janus
síndrome de dificultad respiratoria del adulto
infecções por coronavirus
inibidores de janus quinases
síndrome do desconforto respiratório do adulto
Iastrebner, Marcelo
Castro, Joaquín
García Espina, Edgardo
Lettieri, Carolina
Payaslian, Silvio
Cuesta, María Celia
Gutiérrez Fernández, Pablo
Mandrile, Araceli
Contreras, Angela Paola
Gervasoni, Sebastián
Verde, Gabriel
Galetti, Cayetano
Minoldo, Estefanía
Caruso, Vanesa
Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
topic_facet coronavirus infections
Janus kinase inhibitors
respiratory distress syndrome, adult
infecciones por coronavirus
inhibidores de las cinasas Janus
síndrome de dificultad respiratoria del adulto
infecções por coronavirus
inibidores de janus quinases
síndrome do desconforto respiratório do adulto
author Iastrebner, Marcelo
Castro, Joaquín
García Espina, Edgardo
Lettieri, Carolina
Payaslian, Silvio
Cuesta, María Celia
Gutiérrez Fernández, Pablo
Mandrile, Araceli
Contreras, Angela Paola
Gervasoni, Sebastián
Verde, Gabriel
Galetti, Cayetano
Minoldo, Estefanía
Caruso, Vanesa
author_facet Iastrebner, Marcelo
Castro, Joaquín
García Espina, Edgardo
Lettieri, Carolina
Payaslian, Silvio
Cuesta, María Celia
Gutiérrez Fernández, Pablo
Mandrile, Araceli
Contreras, Angela Paola
Gervasoni, Sebastián
Verde, Gabriel
Galetti, Cayetano
Minoldo, Estefanía
Caruso, Vanesa
author_sort Iastrebner, Marcelo
title Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
title_short Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
title_full Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
title_fullStr Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
title_full_unstemmed Ruxolitinib in severe COVID-19: Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
title_sort ruxolitinib in severe covid-19: results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with covid-19 and severe acute respiratory syndrome
description Introduction: COVID-19 morbimortality is mainly associated with development of severe acute respiratory syndrome (SARS), which has been related to an augmented immune response of the host with elevated circulating cytokines. Methods: In this is a prospective, multicenter, single arm (compared with a historical control), add-on, experimental phase 2 study, ruxolitinib 5 mg BID was added to standard of care in COVID-19 patients. Main objective was to determine efficacy and safety of ruxolitinib in patients with COVID-19-related SARS. Results: Even though we could not show a significant reduction of COVID-19 pneumonia patients requiring intensive care unit admission and mechanical ventilation (primary endpoint), a trend to a lower mortality rate in critical ill patients receiving ruxolitinib was reported. Administered ruxolitinib dose had to be increased according to protocol in 32% of patients, without additional toxicity. Conclusion: Side effects profile was manageable, and no direct organ injury was caused by the study drug. Ruxolitinib had a fast anti-inflammatory effect, and one-third of patients felt well immediately after starting treatment.
publisher Universidad Nacional Cba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
publishDate 2021
url https://revistas.unc.edu.ar/index.php/med/article/view/32800
work_keys_str_mv AT iastrebnermarcelo ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT castrojoaquin ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT garciaespinaedgardo ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT lettiericarolina ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT payasliansilvio ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT cuestamariacelia ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT gutierrezfernandezpablo ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT mandrilearaceli ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT contrerasangelapaola ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT gervasonisebastian ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT verdegabriel ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT galetticayetano ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT minoldoestefania ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT carusovanesa ruxolitinibinseverecovid19resultsofamulticenterprospectivesinglearmopenlabelclinicalstudytoinvestigatetheefficacyandsafetyofruxolitinibinpatientswithcovid19andsevereacuterespiratorysyndrome
AT iastrebnermarcelo ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT castrojoaquin ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT garciaespinaedgardo ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT lettiericarolina ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT payasliansilvio ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT cuestamariacelia ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT gutierrezfernandezpablo ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT mandrilearaceli ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT contrerasangelapaola ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT gervasonisebastian ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT verdegabriel ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT galetticayetano ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT minoldoestefania ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT carusovanesa ruxolitinibencovid19graveresultadosdeunestudiomulticentricoprospectivodebrazounicoydisenoabiertoparaevaluarlaeficaciayseguridaddelruxolitinibenpacientesconcovid19ysindromerespiratorioagudograve
AT iastrebnermarcelo ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT castrojoaquin ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT garciaespinaedgardo ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT lettiericarolina ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT payasliansilvio ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT cuestamariacelia ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT gutierrezfernandezpablo ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT mandrilearaceli ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT contrerasangelapaola ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT gervasonisebastian ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT verdegabriel ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT galetticayetano ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT minoldoestefania ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
AT carusovanesa ruxolitinibeemcovid19graveresultadosdeumestudoabertomulticentricoprospectivodebracounicoparaavaliaraeficaciaesegurancaderuxolitinibeempacientescomcovid19esindromerespiratoriaagudagrave
bdutipo_str Revistas
_version_ 1764819784497627137

Ejemplares similares